Lindsey Shapiro, PhD,  science writer—

The first healthy volunteer has been dosed with an investigational exon-skipping therapy, called PGN-EDO51, for Duchenne muscular dystrophy (DMD) in a Phase 1 trial, the treatment’s developer, PepGen, has announced. The single-ascending dose trial is investigating the treatment’s safety and tolerability in about 40 healthy adult males in Canada.

The Muscular Dystrophy Association (MDA) has launched its 40th annual MDA Shamrocks fundraising campaign — one of the largest St. Patrick’s Day fundraisers in the U.S. — to raise money and to increase awareness of muscular dystrophy (MD) and related neuromuscular disorders. Throughout February and March, thousands…